CTLT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CTLT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Catalent's Short-Term Debt for the quarter that ended in Sep. 2024 was $48 Mil.
Catalent's quarterly Short-Term Debt increased from Mar. 2024 ($47 Mil) to Jun. 2024 ($48 Mil) but then stayed the same from Jun. 2024 ($48 Mil) to Sep. 2024 ($48 Mil).
Catalent's annual Short-Term Debt increased from Jun. 2022 ($31 Mil) to Jun. 2023 ($536 Mil) but then declined from Jun. 2023 ($536 Mil) to Jun. 2024 ($48 Mil).
The historical data trend for Catalent's Short-Term Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalent Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Short-Term Debt | Get a 7-Day Free Trial | 73.00 | 75.00 | 31.00 | 536.00 | 48.00 |
Catalent Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Short-Term Debt | Get a 7-Day Free Trial | 624.00 | 46.00 | 47.00 | 48.00 | 48.00 |
Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.
Thank you for viewing the detailed overview of Catalent's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Michelle R Ryan | director | 214 PARK BLVD S, VENICE FL 34285 |
Joseph Anthony Ferraro | officer: SVP, General Counsel, CCO | 56 EMILY ROAD, FAR HILLS FL 07931 |
David Mcerlane | officer: Group President, Biologics | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Ricky Hopson | officer: VP, Chief Accounting Officer | CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Lisa Evoli | officer: SVP, Chief HR Officer | 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Aristippos Gennadios | officer: See Remarks | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Scott Gunther | officer: See Remarks | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Alessandro Maselli | officer: See remarks | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Matti Masanovich | officer: SVP, Chief Financial Officer | COLLINS & AIKMAN CORPORATION, 250 STEPHENSON HIGHWAY, TROY MI 48083 |
Steven Barg | director | ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019 |
John J Greisch | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Frank A Damelio | director | C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017 |
Stephanie Okey | director | C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
Jonathan Arnold | officer: President, Oral Drug Delivery | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Steven L Fasman | officer: See Remarks | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
From GuruFocus
By Business Wire • 05-29-2024
By Marketwired • 04-27-2024
By PRNewswire • 02-24-2024
By PRNewswire • 04-18-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 04-20-2024
By Business Wire • 04-18-2024
By GuruFocus Research • 02-05-2024
By Business Wire • 11-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.